Clearside rises on starting enrollment in eye-drug trial

Clearside Biomedical,

01/06/2023 16:15

** Shares of drug developer Clearside Biomedical Inc
 CLSD.O  up 4.6% at $1.13
    ** Co opens enrollment in mid-to-late stage trial of
eye-disorder drug CLS-AX
    ** The trial will test the drug in patients with wet
age-related macular degeneration, a chronic eye disorder causing
blurred vision or a blind spot in one's visual field
    ** Co eyes to conduct the trial acroos 30 sites across U.S.
    ** Expect to report topline data in Q3 2024
    ** Stock down 17.5% in last 12 months

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))